Expression of miR-409-5p in gestational diabetes mellitus and its relationship with insulin resistance.
gestational diabetes mellitus
insulin resistance
miR-409-5p
Journal
Experimental and therapeutic medicine
ISSN: 1792-0981
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
13
02
2020
accepted:
19
06
2020
entrez:
29
8
2020
pubmed:
29
8
2020
medline:
29
8
2020
Statut:
ppublish
Résumé
Expression of miR-409-5p in gestational diabetes mellitus (GDM) and its relationship with insulin resistance were explore. One hundred and forty-nine pregnant women who underwent antenatal examination in Taizhou First People's Hospital were divided into a GDM group and a control group according to whether they had GDM or not. Serum miR-409-5p expression of the two groups was detected, and the levels of glycosylated hemoglobin (HbAlc) and other GDM-related biochemical indicators were measured. Fasting plasma glucose (FPG) was determined by glucose oxidase method, fasting insulin (FINS) was detected by radioimmunoassay, and homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. The relationship between miR-409-5p and other biochemical indicators and insulin resistance was analyzed, and logistic multivariate regression was employed to analyze the risk factors of GDM. miR-409-5p was highly expressed in the serum of GDM patients. HbAlc, FPG, FINS, and HOMA-IR in pregnant women in the GDM group were markedly higher than those in the control group. The serum miR-409-5p in GDM pregnant women showed a positive correlation with HbAlc, FPG, FINS, and HOMA-IR (P<0.05). The insulin resistance group presented remarkably higher serum miR-409-5p level than the non-insulin resistance group. Moreover, it was found that elevated miR-409-5p, FINS, and HOMA-IR were all independent risk factors for the onset of GDM. miR-409-5p is highly expressed in the serum of patients with GDM, and it is positively correlated with insulin resistance index of GDM patients, which may be a potential target for clinical diagnosis and treatment of GDM.
Identifiants
pubmed: 32855704
doi: 10.3892/etm.2020.9049
pii: ETM-0-0-9049
pmc: PMC7444361
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3324-3329Informations de copyright
Copyright © 2020, Spandidos Publications.
Références
Mol Cell Endocrinol. 2019 Jun 15;490:1-14
pubmed: 30926524
Diabetologia. 2016 Apr;59(4):873
pubmed: 26857831
Mol Ther Nucleic Acids. 2018 Dec 7;13:154-163
pubmed: 30290307
Obstet Gynecol Sci. 2020 Jan;63(1):19-26
pubmed: 31970124
J Gynecol Obstet Biol Reprod (Paris). 2016 Feb;45(2):105-11
pubmed: 26780845
Prim Care Diabetes. 2018 Dec;12(6):565-573
pubmed: 30115525
Front Endocrinol (Lausanne). 2017 Dec 12;8:345
pubmed: 29312141
Diabet Med. 2014 Aug;31(8):1014-7
pubmed: 24673545
Oncogene. 2012 Oct 18;31(42):4509-16
pubmed: 22179828
J Cell Physiol. 2019 May;234(5):6654-6666
pubmed: 30341900
Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2192-2197
pubmed: 31412738
Biomolecules. 2019 Jan 11;9(1):
pubmed: 30641999
Acta Obstet Gynecol Scand. 2004 Apr;83(4):341-7
pubmed: 15005780
Clin Lab. 2018 Jun 1;64(6):945-953
pubmed: 29945326
J Perinatol. 2016 Feb;36(2):90-4
pubmed: 26562371
Diagn Pathol. 2019 Oct 25;14(1):119
pubmed: 31653266
Eur Rev Med Pharmacol Sci. 2017 Dec;21(24):5702-5710
pubmed: 29272006
Diabetes Care. 2010 Mar;33(3):676-82
pubmed: 20190296
Mol Cell Endocrinol. 2015 Oct 15;414:177-85
pubmed: 26219823
Tumour Biol. 2017 May;39(5):1010428317701647
pubmed: 28459205
J Diabetes Res. 2018 Jun 5;2018:4207067
pubmed: 29967793
Mol Diagn Ther. 2018 Jun;22(3):345-352
pubmed: 29556924
Diabetes. 2016 Jan;65(1):53-61
pubmed: 26696639
EXCLI J. 2017 Dec 12;16:1297-1307
pubmed: 29333131
Biofactors. 2018 Nov;44(6):539-547
pubmed: 30536654
Diabetes Res Clin Pract. 2017 Oct;132:1-9
pubmed: 28783527
Acta Obstet Gynecol Scand. 2017 Jul;96(7):821-827
pubmed: 28276579